Praluent (alirocumab) works by inactivating a protein in the liver called proprotein convertase subtilisin kexin 9 (PCSK9). PCSK9 blocks the receptors that transport LDL into the liver for metabolism (break down). Without these receptors, more LDL (bad) cholesterol remains in the blood.